Implications of Pediatric Inhaled Insulin Approval

The FDA has approved Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older living with type 1 and type 2 diabetes, an expansion of the drug's existing adult indication, which dates to 2014.1 The approval was supported by results from the pivotal INHALE-1 clinical trial, supplemented by more than two decades of safety and efficacy data generated through the drug's development history.

More than 350,000 children and adolescents in the US are living with diabetes, the majority with type 1, requiring lifelong insulin therapy.1 Until now, mealtime insulin management in this population has relied almost exclusively on injectable delivery. The new indication introduces an inhaled alternative that delivers insulin through the lungs using MannKind Corporation's proprietary Technosphere drug-delivery platform, enabling rapid systemic absorption with a pharmacokinetic profile that more closely mimics the body's natural postprandial insulin response.

A key practical distinction is dosing timing: Afrezza is administered at the start of a meal, rather than requiring pre-meal planning.1 In pediatric patients, whose eating habits, activity levels, and daily routines are inherently less predictable than adults, this characteristic may translate to more flexible day-to-day management.

What Are the Manufacturing Implications of Inhaled Insulin Formulations?

The approval is a reminder of how formulation strategy shapes both clinical utility and manufacturing complexity.1 Translating a biologics-based therapy like insulin into a stable, inhalable dry powder requires a significantly different production infrastructure than conventional injectable manufacturing. The Technosphere platform uses a porous particle technology into which insulin is loaded, a process that demands precise control over particle size, morphology, and drug loading to ensure consistent pulmonary deposition and dose reproducibility.

The shift toward inhaled biologics raises important questions about facility design, analytical method development, and regulatory pathway planning.1 Inhalation products must meet stringent requirements for aerodynamic particle size distribution, device-drug interaction characterization, and long-term stability under varying humidity conditions. These technical demands can substantially extend development timelines and capital requirements compared with equivalent injectable programs.

Regulatory submissions for inhaled biologics also carry a distinct documentation burden.1 Bridging adult and pediatric data, as was done here using the INHALE-1 trial alongside the existing adult evidence base, illustrates a development strategy that manufacturers should consider when planning lifecycle extensions for approved inhaled therapies. The pediatric approval also now places Afrezza alongside multiple daily injections and insulin pumps as a recognized option in the American Diabetes Association Standards of Care.

Safety considerations specific to this delivery route remain relevant.1 The prescribing information contraindicates use in patients with chronic lung conditions such as asthma or chronic obstructive pulmonary disease, and requires pulmonary function monitoring at baseline and periodically during treatment. These requirements have direct implications for post-market surveillance design and pharmacovigilance planning for any manufacturer developing inhaled insulin or comparable inhaled biologic products.

Inhaled Dry Powder Delivery Expanding Beyond Diabetes?

The pediatric Afrezza approval is not the only recent development signaling broader momentum in inhaled dry powder therapeutics.2 MannKind and United Therapeutics Corporation announced that they are advancing a dry powder inhalation formulation of ralinepag, an investigational prostacyclin receptor agonist, for pulmonary arterial hypertension and related fibrotic lung diseases. United Therapeutics intends to serve as the primary manufacturer, a structural decision reflecting the specialized production infrastructure these formulations demand. The collaboration builds on a prior partnership that produced Tyvaso DPI, which generated $1.3 billion in revenue in 2025, underscoring the commercial potential that continues to draw development investment toward inhaled delivery platforms.

References

1. MannKind Corporation. MannKind announces FDA approval of Afrezza®, the first and only inhaled mealtime insulin for use in children and adolescents aged 6 and older living with diabetes. Press Release. May 29, 2026. https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-fda-approval-afrezzar-first-and-only-inhaled
2. MannKind Corporation. MannKind announces ralinepag dry powder inhalation (DPI) program to be pursued for pulmonary hypertension and fibrotic lung diseases. Press Release. May 6, 2026. https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-ralinepag-dry-powder-inhalation-dpi-program